

NOVACYT

Novacyt S.A.
 (“Novacyt”, the “Company” or the “Group”)

Result of AGM

The results of the Ordinary General Meeting are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:

1) Approval of the Company’s individual financial statements for the year ended 31 December 2022 (Resolution No. 1),	For	5,065,803	Adopted	87,8432%
	Against	701,067		
	<i>Abstention</i>	155,203		
2) Approval of the Company’s consolidated financial statements for the year ended 31 December 2021 (Resolution No. 2),	For	5,065,803	Adopted	87,8432%
	Against	701,067		
	<i>Abstention</i>	155,203		
3) Allocation of the Company’s loss for the year ended 31 December 2021 (Resolution No. 3),	For	5,039,278	Adopted	87,1800%
	Against	741,039		
	<i>Abstention</i>	141,756		
4) Authorization of the related parties agreements referred to in Articles L. 225-38 <i>et seq.</i> of the French Commercial Code (Resolution No. 4),	For	5, 046,981	Adopted	87,4778%
	Against	722,464		
	<i>Abstention</i>	152,628		
5) Discharge to the Board of Directors (Resolution No. 5),	For	3,946,733	Adopted	67,6976%
	Against	1,883,213		
	<i>Abstention</i>	92,127		
6) Authorisation for the Company to buy back its own shares (Resolution No. 6),	For	4,114,970	Adopted	69,9598%
	Against	1,766,940		
	<i>Abstention</i>	40,163		
7) Ratification of the appointment of a non-voting member (censeur) of the Board of Directors (Resolution No. 7),	For	4,611,646	Adopted	79,5069%
	Against	1,188,665		
	<i>Abstention</i>	121,762		
8) Ratification of the appointment of a non-voting member (censeur) of the Board of Directors (Resolution No. 8),	For	4,819,353	Adopted	82,9845%
	Against	988,178		
	<i>Abstention</i>	114,542		
9) Appointment of a member of the Board of Directors (Resolution No. 9),	For	4,546,913	Adopted	78,1769%
	Against	1,269,269		
	<i>Abstention</i>	105,891		
10) Appointment of a member of the Board of Directors (Resolution No. 10),	For	4,839,961	Adopted	83,2870%
	Against	971,221		
	<i>Abstention</i>	110,891		
11) Reappointment of a board member (Resolution No. 11),	For	4,614,828	Adopted	79,8748%
	Against	1,162,751		
	<i>Abstention</i>	144,494		
12) Reappointment of a board member (Resolution No. 12),	For	4,692,570	Adopted	81,2944%
	Against	1,079,747		
	<i>Abstention</i>	149,756		
13) Powers for formalities (Resolution No. 13),	For	4,993,420	Adopted	85,1472%
	Against	871,033		
	<i>Abstention</i>	57,620		

Number of participating shareholders (by voting form, electronic vote, proxy or present): 639 shareholders representing 5,922,073 shares.

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman
James McCarthy, Acting Chief Executive Officer

+44 (0)23 8074 8830

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780
novacyt@walbrookpr.com

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of *in vitro* diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.

Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com